deltatrials
Completed PHASE2 NCT00089921

SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine

Sponsor: Scios, Inc.

Conditions Arthritis, Rheumatoid
Interventions Placebo SCIO-469
Updated 5 times since 2017 Last updated: Oct 15, 2010 Started: Jul 31, 2004 Completion: Oct 31, 2005

Listed as NCT00089921, this PHASE2 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by Scios, Inc., it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Scios, Inc.
Data source: Scios, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.